摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(3-Pyridinylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid | 1135299-25-0

中文名称
——
中文别名
——
英文名称
2-[(3-Pyridinylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid
英文别名
2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidine-4-carboxylic acid
2-[(3-Pyridinylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid化学式
CAS
1135299-25-0
化学式
C13H10N4O2S
mdl
——
分子量
286.314
InChiKey
LKGCKISEGRISGU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    116
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor
    摘要:
    We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diabetes, asthma and COPD. Furthermore, preliminary pharmacokinetic analysis has revealed compounds with profiles suitable for either inhaled or systemic routes of administration. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.040
  • 作为产物:
    描述:
    参考文献:
    名称:
    Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor
    摘要:
    We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diabetes, asthma and COPD. Furthermore, preliminary pharmacokinetic analysis has revealed compounds with profiles suitable for either inhaled or systemic routes of administration. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.040
点击查看最新优质反应信息

文献信息

  • [EN] THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS DÉTHIÉNOPYRIMIDINE ET COMPOSITIONS
    申请人:VERNALIS R & D LTD
    公开号:WO2009037468A1
    公开(公告)日:2009-03-26
    Compounds of formula (I) are A2B wherein R1 and R2 are independently selected from hydrogen, or optionally substituted CrC6 alkyl, C1-C6 alkoxy-( C1-C6 )-alkyl, C3-C8 cycloalkyl, aryl, heteroaryl, aryl-( C1-C6 )-alkyl, or heteroaryl-( C1-C6 )-alkyl; or R-1 and R2 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R3 and R4 are independently selected from hydrogen, or optionally substituted C1-C6 alkyl, C1-C6 alkoxy-( C1-C6 )-alkyl, C3- C8 cycloalkyl, aryl, heteroaryl, aryl-( C1-C6 )-alkyl, or heteroaryl- C1-C6 )-alkyl; or R3 and R4 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R5 and R6 are independently selected from hydrogen, C1-C6 alkyl, aryl, aryl-( C1-C6 )-alkyl, - NHR7 -N(-R8)-R9, -NH-(C=O)-R10, -(C=O)-NH-R11, -(C=O)-O-R12, or halo; and R7, R8, R9, R10, R-11, and R12 are independently selected from C1-C6 alkyl, aryl, aryl-( C1-C6 )-alkyl and heteroaryl.
    式(I)的化合物为A2B,其中R1和R2独立选择氢,或可选取代的CrC6烷基,C1-C6烷氧基-(C1-C6)-烷基,C3-C8环烷基,芳基,杂芳基,芳基-(C1-C6)-烷基,或杂芳基-(C1-C6)-烷基;或R1和R2与它们附着的氮原子一起形成可选取代的5-或6-成员环;R3和R4独立选择氢,或可选取代的C1-C6烷基,C1-C6烷氧基-(C1-C6)-烷基,C3-C8环烷基,芳基,杂芳基,芳基-(C1-C6)-烷基,或杂芳基-(C1-C6)-烷基;或R3和R4与它们附着的氮原子一起形成可选取代的5-或6-成员环;R5和R6独立选择氢,C1-C6烷基,芳基,芳基-(C1-C6)-烷基,-NHR7-N(-R8)-R9,-NH-(C=O)-R10,-(C=O)-NH-R11,-(C=O)-O-R12,或卤素;而R7、R8、R9、R10、R-11和R12独立选择C1-C6烷基,芳基,芳基-(C1-C6)-烷基和杂芳基。
  • THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS
    申请人:Jordan Allan
    公开号:US20100298349A1
    公开(公告)日:2010-11-25
    Compounds of formula (I) are A 2B wherein R 1 and R 2 are independently selected from hydrogen, or optionally substituted CrC6 alkyl, C 1 -C 6 alkoxy-(C 1 -C 6 )-alkyl, C 3 -C 8 cycloalkyl, aryl, heteroaryl, aryl-(C 1 -C 6 )-alkyl, or heteroaryl-(C 1 -C 6 ) -alkyl; or R −1 and R 2 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 3 and R 4 are independently selected from hydrogen, or optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy-(C 1 -C 6 )-alkyl, C 3 -C 8 cycloalkyl, aryl, heteroaryl, aryl-(C 1 -C 6 )-alkyl, or heteroaryl-C 1 -C 6 )-alkyl; or R 3 and R 4 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 5 and R 6 are independently selected from hydrogen, C 1 -C 6 alkyl, aryl, aryl-(C 1 -C 6 )-alkyl, —NHR 7 —N(—R 8 )—R 9 , —NH—(C═O)—R 10 , —(C═O)—NH—R 11 , —(C═O)—O—R 12 , or halo; and R 7 , R 8 , R 9 , R 10 , R −11 , and R 12 are independently selected from C 1 -C 6 alkyl, aryl, aryl-(C 1 -C 6 )-alkyl and heteroaryl.
    公式(I)的化合物为A2B,其中R1和R2独立地选择氢,或者可选地取代的CrC6烷基,C1-C6氧代烷基,C3-C8环烷基,芳基,杂环芳基,芳基-(C1-C6)-烷基,或杂环芳基-(C1-C6)-烷基;或者R-1和R2与它们附着的氮原子一起形成可选地取代的5-或6-成员环;R3和R4独立地选择氢,或者可选地取代的C1-C6烷基,C1-C6氧代烷基,C3-C8环烷基,芳基,杂环芳基,芳基-(C1-C6)-烷基,或杂环芳基-(C1-C6)-烷基;或者R3和R4与它们附着的氮原子一起形成可选地取代的5-或6-成员环;R5和R6独立地选择氢,C1-C6烷基,芳基,芳基-(C1-C6)-烷基,—NHR7—N(—R8)—R9,—NH—(C═O)—R10,—(C═O)—NH—R11,—(C═O)—O—R12,或卤素;而R7、R8、R9、R10、R-11和R12独立地选择C1-C6烷基,芳基,芳基-(C1-C6)-烷基和杂环芳基。
  • US8354415B2
    申请人:——
    公开号:US8354415B2
    公开(公告)日:2013-01-15
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-腈 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2-乙酸,1,4-二氢-4-羰基-5-苯基-,甲基酯 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(4-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙酸,[[5-(4,5-二甲基-2-苯基噻吩并[2,3-d]嘧啶-6-基)-1,3,4-噁二唑-2-基]硫代]-,乙基酯 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇